Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/18464 |
Resumo: | OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p |
id |
USP-19_d4b8351c33e074c353dde0516362bc11 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/18464 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction Phosphodiesterase type 5 inhibitorsTadalafil citrateTotal antioxidant statusTotal oxidant statusProlidase OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (pHospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2010-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1846410.1590/S1807-59322010001200014Clinics; Vol. 65 No. 12 (2010); 1311-1314 Clinics; v. 65 n. 12 (2010); 1311-1314 Clinics; Vol. 65 Núm. 12 (2010); 1311-1314 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/18464/20527Savas, MuratYeni, ErcanVerit, AyhanGulum, MehmetAksoy, NurtenCiftci, HalilCelik, HakimAltunkol, AdemOncel, Halilinfo:eu-repo/semantics/openAccess2012-05-23T11:25:42Zoai:revistas.usp.br:article/18464Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-23T11:25:42Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction |
title |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction |
spellingShingle |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction Savas, Murat Phosphodiesterase type 5 inhibitors Tadalafil citrate Total antioxidant status Total oxidant status Prolidase |
title_short |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction |
title_full |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction |
title_fullStr |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction |
title_full_unstemmed |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction |
title_sort |
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction |
author |
Savas, Murat |
author_facet |
Savas, Murat Yeni, Ercan Verit, Ayhan Gulum, Mehmet Aksoy, Nurten Ciftci, Halil Celik, Hakim Altunkol, Adem Oncel, Halil |
author_role |
author |
author2 |
Yeni, Ercan Verit, Ayhan Gulum, Mehmet Aksoy, Nurten Ciftci, Halil Celik, Hakim Altunkol, Adem Oncel, Halil |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Savas, Murat Yeni, Ercan Verit, Ayhan Gulum, Mehmet Aksoy, Nurten Ciftci, Halil Celik, Hakim Altunkol, Adem Oncel, Halil |
dc.subject.por.fl_str_mv |
Phosphodiesterase type 5 inhibitors Tadalafil citrate Total antioxidant status Total oxidant status Prolidase |
topic |
Phosphodiesterase type 5 inhibitors Tadalafil citrate Total antioxidant status Total oxidant status Prolidase |
description |
OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/18464 10.1590/S1807-59322010001200014 |
url |
https://www.revistas.usp.br/clinics/article/view/18464 |
identifier_str_mv |
10.1590/S1807-59322010001200014 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/18464/20527 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 65 No. 12 (2010); 1311-1314 Clinics; v. 65 n. 12 (2010); 1311-1314 Clinics; Vol. 65 Núm. 12 (2010); 1311-1314 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222755626418176 |